Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.

NCT07654530 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancers (BTC)

Interventions

DRUG: Sintilimab + Ipilimumab (N01) + AG
DRUG: Sintilimab Combined with Albumin-bound Paclitaxel and Gemcitabine (AG)

Sponsor

Tianjin Medical University Cancer Institute and Hospital